Will This Price Target Decrease Hurt Alere (ALR) Stock Today?

Story updated at 9:55 a.m. to reflect market activity.

NEW YORK (TheStreet) -- Jefferies lowered its price target for Alere (ALR) to $40 from $45 Tuesday, reiterating its "buy" rating for the stock.

Alere fell -0.5% to $34.57 in morning trading.

The analyst firm also lowered its EPS estimates for the company through 2015. Jefferies analysts noted that Alere has a tough second quarter, but said the company is "officially in reset mode" as it tries to remake itself.

Must read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

--------------------

Separately, TheStreet Ratings team rates ALERE INC as a Buy with a ratings score of B-. TheStreet Ratings Team has this to say about their recommendation:

"We rate ALERE INC (ALR) a BUY. This is driven by a few notable strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income."

ALR ChartALR data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

FTC Approves Abbott's Acquisition of Alere, Stock Jumps

FTC Approves Abbott's Acquisition of Alere, Stock Jumps

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

Abbott CEO: Another Alere-Related Divestiture Coming Soon

Abbott CEO: Another Alere-Related Divestiture Coming Soon

Alere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings

Alere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings

Quidel Diversifies With Alere's Triage Assets

Quidel Diversifies With Alere's Triage Assets